Male Hypogonadism Market - Rise In Awareness about the Available Treatment Options And Increase in Incidence of Male Hypogonadism Are Major Factors That Drive the Growth of the Market

By 2022, the male gonadal stimulator market is estimated to reach $ 323 million by 2022 and is expected to grow at a CAGR of 3.1% from 2016 to 2022. The pituitary disease sector accounts for nearly half of the total market share in 2015 and is expected to remain dominant over the analysis period.

Hypogonadism in the male is a clinical condition in which the testes fail to produce sufficient testosterone, resulting in decreased development of muscle mass, loss of body hair growth, development of breast tissue and a lack of vocalization. Growth in the male hypogonadism market is due to increased prevalence and frequency of patients with testosterone deficiency, increased rates of infertility, and increased patient awareness of options for treating STDs according to certain campaigns conducted by governments. In addition, the risk of germs is very high in the elderly population and in obese and diabetic populations.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/1874

Key players have adopted product approval as their key strategy to cater to the changing needs of the industry. There is high competition among key players to launch innovative, technologically advanced products to increase their market share and serve the patients in a better way.

Major players operating in this market include
• AbbVie Inc.
• Allergan plc
• AstraZeneca plc
• Bayer AG
• Eli Lilly and Company Ltd.
• Endo International plc
• Merck & Co. Inc.
• Ferring Holding S.A.
• Finox Biotech
• IBSA Institut Biochimque SA
• Laboratoires Genevrier
• Teva Pharmaceutical Industries Ltd.
 
The increase in the elderly population and the occurrence of chronic lifestyle disorders (obesity and diabetes) are expected to further stimulate market growth. However, the high side effects of all testosterone products are expected to hamper the growth of the testosterone replacement therapy (TRT) segment in this market. Technology advancement is expected to provide new opportunities during the forecast period.

Make an Enquiry before Buy @ https://www.alliedmarketresearch.com/purchase-enquiry/1874

North America accounted for the majority of market share (more than three quarters) in 2015 and is expected to dominate throughout the forecast period. This is due to an increase in the population suffering from primary and secondary causes of hypogonadism and an increase in patient awareness of the usefulness of treatment options. The high adoption rate of high technology products and the presence of highly sophisticated medical infrastructure are expected to create new growth opportunities for key players in this market. Europe is expected to register the highest CAGR of 7.2% during the analysis period with an increase in the adoption of western lifestyle, an increase in unhealthy eating habits, and an increase in the population with hypogonadism. Growth of urbanization.

Key Findings of the Male Hypogonadism Market
• By drug therapy, gonadotropin and gonadotropin-releasing hormones therapy segment is projected to grow at the highest CAGR of 8.9% during the forecast period.
• Pituitary disorders segment is expected to grow at the CAGR of 3.2%.
• Injectables accounted for nearly half of the market share in 2015.
• North America accounted for majority of the share (more than three-fourths) in 2015, and is expected to remain dominant throughout the forecast period.
• U.S. accounted for the majority share in the North American market in 2015, and the Mexican market is expected to grow at the highest CAGR of 6.7%.

Access Full Summery @ https://www.alliedmarketresearch.com/male-hypogonadism-market

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:

David Correa

5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States

Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975

help@alliedmarketresearch.com

This release was published on openPR.